BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
about
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibitTargeting folate receptor alpha for cancer treatmentBiology of the major facilitative folate transporters SLC19A1 and SLC46A1Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targetsStructures of human folate receptors reveal biological trafficking states and diversity in folate and antifolate recognitionPathogenesis of ovarian cancer: clues from selected overexpressed genes.Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over theTherapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporterThe human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors.Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer.Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transFunctional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human TumorsNovel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.Improved biochemical strategies for targeted delivery of taxoidsTargeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.The antifolatesTumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide BiosySynthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expressionOptimal treatment for relapsing ovarian cancer.Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates.The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.Identification of a peptide for folate receptor alpha by phage display and its tumor targeting activity in ovary cancer xenograft.
P2860
Q24631090-ED741C36-9E07-43EA-819C-F36E555CAEDFQ26744215-C5F9AE5E-867C-4355-BAA5-C83E362603BEQ26998717-10DF8DB2-DB79-41B9-8CA6-291BF68F295DQ27678339-94A9E4B2-9F66-4B21-82A0-8C59A61E8C29Q27679502-9F001E53-70C3-4280-8C02-632698BBED1EQ33651139-B45431BD-E434-4A31-A209-0A583367FF56Q33720633-17EDC659-259B-4E27-A3DC-B31342DB4063Q34218576-38D6A269-D851-46A6-B91B-AFFC10230828Q34297931-03ACF42C-1A6A-43D0-A520-A778221A117BQ34310128-8B0C1C88-74B4-4D03-8C31-3F67273E8E14Q34333704-B363D954-C234-4A24-ADAB-29A93E794D83Q34658009-336E9061-70C4-40FA-ABE1-2FFD0BC0CEC8Q34833628-7CE17578-B760-4E0F-940C-9FAAD6A7C793Q35639774-FA59B05B-2972-4E67-85F8-BDA893E2758FQ35783179-865E822E-AFE9-430C-B518-1F1796DA8B92Q36294436-C3519912-18FC-4455-AC11-21643D8D9FFCQ36467564-D4309634-BB6A-4FDB-8D7F-EB098E49516BQ36467569-AB850CA8-29D5-422E-9835-056A5DF52182Q36642502-F518E988-866E-498C-BD03-42FABE9F9DE5Q36733474-1D22D4E5-A272-4EFF-946D-7B73B539D96BQ37162634-BC42ABB5-E95A-4595-8BE8-126D2214E921Q37183495-5ADEC71F-8ECB-4851-8A95-6BF121387BC0Q37246257-084E27F7-29FE-4762-BAE8-6013D60C8CF9Q37356225-634B47E3-39B3-4648-A0C9-3AC1AA365201Q37425429-80022FBE-A387-4456-A72F-1050DBF15513Q37479804-1912D3A1-68E1-4A02-8A19-A063FB4A292FQ37553497-9F9D1A17-79F9-49E0-A539-DEA22A124420Q37799929-720A496B-4F2B-47B8-9A37-BA251B38DA7BQ37992086-2488C5D9-2787-4506-B05F-3089416CFA7BQ38524502-ED9F24A7-2B62-4AA4-AA84-7BC430DA37C7Q38718741-DA8282F7-8488-4EAB-9DFE-7B116AE09915Q50062142-B30F646F-D24F-46FF-A3A7-AD1F5F76DC00Q55061789-38FBC258-7D9F-451C-BEB9-A9A1D7440F99
P2860
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@ast
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@en
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@nl
type
label
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@ast
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@en
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@nl
prefLabel
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@ast
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@en
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@nl
P2093
P1433
P1476
BGC 945, a novel tumor-selecti ...... eceptor-overexpressing tumors.
@en
P2093
Ann L Jackman
David D Gibbs
Davinder S Theti
Elisa Henderson
Florence Raynaud
Fraser Mitchell
Martin D Forster
Matthew Green
Melanie Valenti
Nadya Wood
P304
11721-11728
P356
10.1158/0008-5472.CAN-05-2034
P407
P577
2005-12-01T00:00:00Z